The novel imidazodiazepine derivatives of the formula: ##STR1## wherein the substituents are as described in the specification, can be used for the control or prevention of epileptic seizures, anxiety, tension and excitation states, sleep disorders, schizophrenic symptoms, hepatic encephalopathy and senile dementia, as well as, in the partial or complete antagonization of undesired side-effects of substances acting on benzodiazepine receptors after over-dosage or after their use in intensive medicine and in anesthesia.

Hoffmann-La Roche Inc.

Imidazodiazepine derivatives

The present invention provides compounds of formula I which are capable of inhibition of the activation of hNav1.1 or hNav1.6 sodium channels in neurons. Pharmaceutical compositions comprising these compounds are also provided. Methods for prevention and treatment of neurological disorders, including, for example, seizures and seizure disorders, including Lennox-Gastaut Syndrome, Dravet syndrome, epileptic encephalopathies, autism, Familial hemiplegic migraine (FHM), anxiety disorders, including Post-traumatic stress disorder (PTSD), panic disorder and obsessive-compulsive disorder, neuropathic pain, and Rett syndrome by administration of these compounds are also provided.

THE JOHNS HOPKINS UNIVERSITY

gerstmann-straussler-scheinker disease/seizures

Imidazodiazepine derivatives

Derivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium channels

Rufinamide and derivatives and their use in modulating the gating process of human voltage-gated sodium channels

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen